A Phase 2 Open-Label Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Patients With Homozygous Familial Hypercholesterolemia (HoFH)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2018
Price : $35 *
At a glance
- Drugs Vupanorsen (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- Sponsors Akcea Therapeutics
- 29 Nov 2018 Status changed from recruiting to withdrawn prior to enrolment.
- 31 Aug 2018 Biomarkers information updated
- 23 Apr 2018 Status changed from not yet recruiting to recruiting.